Pharmaceutical Intelligence for Consultancies

Close Icon We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Products:

Pharma Consulting

Conferences 2021

Awards

Upcoming Webinars

Webinar recordings

Close Icon

Global Search Configuration

Search Site Products & Services
Close Icon

Search by Keyword

Focus
Needs

Your trusted pharma partner

With the pharma and healthcare sector facing increasing challenges, your clients rely more than ever on independent intelligence. Pharma Intelligence will help you make smart decisions and stay ahead of a fast changing market.

What we offer

As the trusted partner of the top 50 pharmaceutical companies and 10 contract research organizations, our wide range of solutions cover early phase, clinical R&D, portfolio and strategy, regulatory and commercial planning and analysis.

We cover the life sciences business from drug and device discovery and development to regulatory approval, and drug reimbursement to lifecycle management. And we give you access to past, current and future trends and analysis.

How it helps

Whether you’re working on your next business pitch, engaging on a project for an existing client or working on due diligence for a proposed merger or acquisition; our pharmaceutical intelligence helps you meet the demands of dynamic markets and changing customer needs, with:

Expert analysis of key pharma sectors
In-depth knowledge from drug discovery to market access
Global coverage including digital health, R&D, and emerging markets
Precise analysis and data
Customized reports

Our unique strengths

Understand your clients’ world

Gain a comprehensive understanding of the global pharma market with our complete coverage.

Stay on top of the details

We’ll keep you in touch with complex regulatory and pricing and reimbursement issues.

Think ahead

Respond to market events, identify opportunities and anticipate changes by tracking drug pipelines, patent expiration and commercial activities influencing the landscape.

Deliver tailored solutions

Use our data and insight to create solutions to suit your clients’ needs.

Benefit from a dedicated service

Our services come with dedicated client service and analyst support.

View more
View Less

Relevant products

HBW Insight: Health, Beauty and Wellness

The single most comprehensive consumer healthcare information source covering regulatory, legislative, legal and commercial news across the over the counter medicines, vitamins and dietary supplements, and cosmetics industries.

Key benefits:

Get a global view
Be the first to know
Go beyond the news

Generics Bulletin

A well-respected and trusted industry source for the last 15 years, Generics Bulletin from Informa Pharma Intelligence provides in-depth news and analysis on issues that matter most to businesses across the generics, biosimilars and value-added medicines industries.

Key benefits:

Ask-the-Analyst™ Service
A powerful online platform
In-depth content coverage

Pharmaprojects: track pharma R&D

The industry’s most trusted drug development database, Citeline's Pharmaprojects has been covering pharma R&D across global markets for 35+ years. With 68,000+ drug profiles including 15,000 drugs in active development, it’s the go-to resource for preclinical, clinical, and pipeline coverage, and lifecycle management tracking.

Key benefits:

Curated by experts
Drug R&D landscape
Historical trends

Pink Sheet

US FDA Advisory Committees Could Get Revamp With A Focus On Science Over Emotion

CDER Director Cavazzoni also wants to loosen conflict of interest rules and improve technology for remote meetings. Given FDA’s approval of Aduhelm, her comments, made in a prerecorded interview for the BIO Digital annual meeting, may raise some eyebrows. Industry is also working on recommendations for the agency on the topic.

View article
Generics Bulletin

Overseas API Manufacturing Identified As Key Vulnerability In US Supply Chain

After US President Joe Biden launched a review of the country’s API supply chain, the task force has reported back with key vulnerabilities that contribute to drug shortages and supply risks during a global public health emergency. According to the report, the lack of geographic diversity and dependence on foreign nations and anti-competitive actions by foreign nations are key areas of concern.

View article
Scrip

Biogen/Sage’s Zuranolone Data May Not Be Enough For Tough Commercial Landscape

The drug may have enough efficacy for approval, but data fell short of the benchmark seen as necessary for commercial adoption.

View article
Scrip

Novavax’s Latecomer COVID-19 Vaccine Impresses With 90% Efficacy Result

Arriving two to three months later than planned, Novavax’s nanoparticle-based vaccine is still a welcome addition to the field, for both rich and poor countries.

View article
Scrip

Quick Listen: Scrip’s Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: a ground-breaking approval for Alzheimer’s in the US; LAG-3 inhibitors and new Keytruda data generate excitement at ASCO; and clinical progress for another COVID-19 vaccine.

View article
HBW Insight

Bayer Leads Push For Self-Care In India As Local Business Launches

Bayer has launched a dedicated Consumer Health business in India to market products in key OTC categories. The company is also working to bring different stakeholders together through the creation of a new organization dedicated to promoting self-care in the South Asian country.

View article
HBW Insight

New York’s Age Restrictions On Weight Loss, Sports Supplement Sales Fail To Fly

New York legislation to restrict sales of weight loss and sports nutrition supplements to minors failed without reaching a vote before the end of the session. But the proposal will continue to be a challenge for industry in New York as well as around the country.

View article
Biomedtracker, Datamonitor Healthcare

Plan for 2021 ASCO with Pharma Intelligence

The Pharma Intelligence analyst team will be covering the 2021 ASCO virtual meeting from June 4-8, 2021.

Single report
Generics Bulletin

Celltrion Opens Up Canadian Market For Remsima SC

Celltrion has pushed into another new market with its Remsima SC subcutaneous version of infliximab, launching the innovative biosimilar in Canada.

View article
Pink Sheet

Aducanumab Accelerated Approval Reflects US FDA Flexibility But Raises Doubts About Confirmatory Trial

Biogen/Eisai Alzheimer’s drug wins agency nod on basis of amyloid plaque reduction, a surprising use of the accelerated approval pathway that was not considered by an FDA advisory committee; approval raises feasibility questions about confirmatory trial and daunting prospect of market withdrawal if studies fail to verify clinical benefit.

View article
Scrip

IQVIA Biotech’s Sockalingam On Clinical Research Virtualization In APAC

In this audio interview, the head of IQVIA Biotech (Japan-Asia Pacific) talks to Scrip on a range of aspects around digitalization and virtualization of clinical research in the region, including sharply reduced site contracting timelines. He also touches on the digital product launch efforts that are currently a reality in several markets.

View article
Datamonitor Healthcare

Top 10 Best-Selling Drugs of 2020

One hundred billion dollars. That is the combined revenue of the top 10 pharmaceuticals in 2020, marking the first year in which this threshold has been crossed.

Topic Drug Review Drug Pricing

View article
HBW Insight

US FDA’s Preferred Special Treatment For Cannabinoids Points To Mistreating Industry

Senate bill provision allowing FDA to develop unique labeling and packaging for cannabinoid supplements and foods is unnecessary, as the products should following existing labeling regulations, says CRN chief Steve Mister.

View article
Pink Sheet, Scrip

Drug Pricing eBook

Tap into expert coverage of the complex world of drug pricing with insights from analysts at Scrip and Pink Sheet. This eBook includes vital information about issues affecting drug pricing for the US, EU, and other global markets, including patient access, regulatory issues, commercial challenges, value-based pricing, and more.

Topic Drug Pricing

View article
Scrip

UK Trial Could Help Pick Best Covid Vaccine Boosters

Results will be important in fight against new variants, for second-generation vaccines and AstraZeneca’s controversy-hit jab.

View article